FDA Accepts Verastem NDA for Priority Review, Stock Increases 20% (Update)


US Food and Drug Administration (FDA) Headquarters

the grandparents

We will see (NASDAQ:VSTM) shares soared 20% in after-hours trading on news that the FDA has accepted for priority review the company’s new drug application for accelerated approval of its drugs avutometinib and defactinib in the treatment of ovarian cancer, with a



Source link

  • Related Posts

    Davos 2026: N Chandrasekaran, 6 more Indian CEOs to attend Trump reception dinner. Find the guest list here

    US President Donald Trump is scheduled to meet a host of Indian business leaders on the sidelines of the ongoing World Economic Forum (WEF) in Davos. A delegation of Indian…

    Client Challenge

    Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to continue. A required part of this site could not load. This could be due to a browser extension,…

    Leave a Reply

    Your email address will not be published. Required fields are marked *